NCT03225690

Brief Summary

American Society of Anaesthesiologist physical status (ASA) I-III 105 patients who undergoing major abdominal surgery in obstetric and gynaecology clinic were recruited to this study. Patients were randomized into the 3 groups. Lumbar epidural catheter will be inserted to the all patients. After than anaesthesia induction will provide with 2 mg/kg propofol and 0.6 mg/kg rocuronium. Desflurane and azot protoxit (N2O)-O2 will use for anaesthesia maintenance. During surgical operation, 0.3 microgram/kg/h remifentanil infusion will continuous till the end of surgery. In group I, 2 ml serum physiologic (0.9 NaCL)will apply from epidural catheter before surgical incision. In group II, 1 mg morphine will apply from epidural catheter before surgical incision. In group III, 1 mg morphine will apply from epidural catheter at the time point of peritoneum is closed. Epidural patient controlled analgesia will provide with bupivacaine for postoperative analgesia. Postoperative pain will be assessed with numerical pain scale. Postoperative analgesic requirement will be calculated. Hyperalgesia will detect with algometer and von Frey ligaments.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
105

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jul 2017

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 2, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

July 19, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 21, 2017

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

March 5, 2018

Status Verified

November 1, 2017

Enrollment Period

1.4 years

First QC Date

June 2, 2017

Last Update Submit

March 2, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative analgesic requirement

    Calculation of epidural bupivacain consumption

    Till the postoperative 24th hour.

Secondary Outcomes (1)

  • Algometer values

    Till the postoperative 24th hour.

Study Arms (3)

serum physiologic

PLACEBO COMPARATOR

2 ml serum physiologic will apply via epidural catheter before surgical incision.

Drug: Serum physiologic

Preemptive Morphine

ACTIVE COMPARATOR

1 mg morphine will apply via epidural catheter before surgical incision.

Drug: Morphine

Morphine

ACTIVE COMPARATOR

1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.

Drug: Morphine

Interventions

Prevention of remifentanil induced hyperalgesia

Also known as: Group I-II
MorphinePreemptive Morphine

For placebo, serum physiologic will use

Also known as: Group III
serum physiologic

Eligibility Criteria

Age20 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA I-III patients
  • Patients who undergoing major abdominal surgery

You may not qualify if:

  • ASA IV and up
  • Coagulopathy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Çukurova University Balcalı Hospital

Adana, 01380, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Hyperalgesia

Interventions

Morphine

Condition Hierarchy (Ancestors)

Somatosensory DisordersSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Morphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Study Officials

  • Ebru Biricik

    Cukurova University

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

June 2, 2017

First Posted

July 21, 2017

Study Start

July 19, 2017

Primary Completion

December 1, 2018

Study Completion

December 1, 2018

Last Updated

March 5, 2018

Record last verified: 2017-11

Data Sharing

IPD Sharing
Will not share

Locations